Comparison of Relapse and Treatment Failure Rates Among Patients With Neuromyelitis Optica

Abstract

Initial treatment with rituximab, mycophenolate, and, to a lesser degree, azathioprine significantly reduces relapse rates in NMO and NMO spectrum disorder patients. Patients for whom initial treatment fails often achieve remission when treatment is switched from one to another of these drugs.